Publications

Publications Search

Search for publications by author
Search for publications by abstract keyword(s)

Molecular markers guiding thyroid cancer management

Abstract

The incidence of thyroid cancer is rapidly increasing, mostly due to the overdiagnosis and overtreatment of differentiated thyroid cancer (TC). The increasing use of potent preclinical models, high throughput molecular technologies, and gene expression microarrays have provided a deeper understanding of molecular characteristics in cancer. Hence, molecular markers have become a potent tool also in TC management to distinguish benign from malignant lesions, predict aggressive biology, prognosis, recurrence, as well as for identification of novel therapeutic targets. In differentiated TC, molecular markers are mainly used as an adjunct to guide management of indeterminate nodules on fine needle aspiration biopsies. In contrast, in advanced thyroid cancer, molecular markers enable targeted treatments of affected signalling pathways. Identification of the driver mutation of targetable kinases in advanced TC can select treatment with mutation targeted tyrosine kinase inhibitors (TKI) to slow growth and reverse adverse effects of the mutations, when traditional treatments fail. This review will outline the molecular landscape and discuss the impact of molecular markers on diagnosis, surveillance and treatment of differentiated, poorly differentiated and anaplastic follicular TC.

Type Journal
ISBN 2072-6694 (Print) 2072-6694 (Linking)
Authors Nylen, C.; Mechera, R.; Marechal-Ross, I.; Tsang, V.; Chou, A.; Gill, A. J.; Clifton-Bligh, R. J.; Robinson, B. G.; Sywak, M. S.; Sidhu, S. B.; Glover, A. R.
Responsible Garvan Author Dr Anthony Glover
Publisher Name Cancers
Published Date 2020-08-01
Published Volume 12
Published Issue 8
Published Pages 2164
Status Always Electronic
DOI 10.3390/cancers12082164
URL link to publisher's version https://www.ncbi.nlm.nih.gov/pubmed/32759760